Cardiol Therapeutics

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.

Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study.

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care.

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced plans to expand its MAVERIC clinical development program with the launch of MAVERIC-2, a late-stage trial aimed at evaluating its lead drug candidate, CardiolRx, in patients with recurrent pericarditis. The trial is expected to begin in Q4 2024 at major pericardial disease centers in the USand Europe.

Cardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trial

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy.

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has successfully raised a total of US$15.5 million through a public offering. The company announced that Canaccord Genuity (TSX:CF, LSE:CF) has exercised its over-allotment option in full, purchasing an additional 1,265,625 Class A common shares at $1.60 per share.

Cardiol Therapeutics raises $15.5M following over-allotment option exercise

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share (the "Offering Price") for gross proceeds of US$13.5 million (the "Offering"), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the "Over-Allotment Option"), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions. After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000.

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), a clinical-stage life sciences company focused on heart disease treatments, announced on Wednesday it is raising US$13.5 million through a public offering of 8,437,500 Class A common shares priced at $1.60 per share. The company said it plans to use the net proceeds from the offering to advance the clinical development of its lead product, CardiolRx, for the treatment of recurrent pericarditis, a condition involving inflammation of the heart's outer lining.

Cardiol Therapeutics prices $13.5M public offering

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has reached its target enrollment of 100 patients in the ARCHER trial, a Phase II randomized, double-blind, placebo-controlled study evaluating CardiolRx for myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients," said Andrew Hamer, chief medical officer at Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL).

Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in "ARCHER", its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients.

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has completed its Phase 2 MAvERIC-Pilot study investigating the impact of its novel therapy CardiolRx in patients with recurrent pericarditis and it will be presenting the results at American Heart Association Scientific Sessions 2024. The company said full clinical data from the trial will be reported during an oral presentation at the event on Monday, November 18, 2024, starting at 9:45am.

Cardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis study

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024 Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m.

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGM When: June 26, 2024, at 4:30 p.m.

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) released data from its Phase II MAvERIC-Pilot study demonstrating that its lead drug candidate CardiolRx significantly reduces pericarditis pain and inflammation, showing promise as a non-immunosuppressive treatment option. The study, which assessed the efficacy of CardiolRx in treating symptomatic recurrent pericarditis, revealed a significant reduction in patient-reported pericarditis pain, the primary efficacy endpoint.

Cardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammation

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ("TP"), as well as normalization of inflammation - as measured by C-reactive protein ("CRP") - in 80% of patients with elevated CRP at baseline.

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Acrivon Therapeutics Inc

Aquestive Therapeutics Inc

Bioventus

Heron Therapeutics

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy From a Recovering Industry

Cardiol Therapeutics (NASDAQ: CRDL ) just reported results for the first quarter of 2024. Cardiol Therapeutics reported earnings per share of -10 cents.

CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) showcased promising developments in its Phase II clinical trial, ARCHER, during an oral presentation at the World Congress on Acute Heart Failure 2024. The event provided a platform for Univ.

Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024 Toronto, Ontario--(Newsfile Corp. - May 14, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis ("ARCHER") was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal - the annual congress of the Heart Failure Association of the European Society of Cardiology ("ESC"). The trial design, rationale, and blinded baseline data on the first 50 patients randomized into ARCHER was presented by Univ.

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.

News for Cardiol Therapeutics Stock (CRDL)